12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

ADC Therapeutics, BioAtla deal

BioAtla's VivaMab therapeutic development division granted ADC Therapeutics rights to VivaMab's VM101 for hematologic cancers. VivaMab will provide development support and is eligible to receive milestones and royalties. ADC Therapeutics plans to start...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >